CoChat

The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.

Epigenetic modulation of inflammation and synaptic plasticity promotes resilience against stress in mice

Open access

Abstract

Major depressive disorder is associated with abnormalities in the brain and the immune system. Chronic stress in animals showed that epigenetic and inflammatory mechanisms play important roles in mediating resilience and susceptibility to depression. Here, through a high-throughput screening, we identify two phytochemicals, dihydrocaffeic acid (DHCA) and malvidin-3′-O-glucoside (Mal-gluc) that are effective in promoting resilience against stress by modulating brain synaptic plasticity and peripheral inflammation. DHCA/Mal-gluc also significantly reduces depression-like phenotypes in a mouse model of increased systemic inflammation induced by transplantation of hematopoietic progenitor cells from stress-susceptible mice. DHCA reduces pro-inflammatory interleukin 6 (IL-6) generations by inhibiting DNA methylation at the CpG-rich IL-6 sequences introns 1 and 3, while Mal-gluc modulates synaptic plasticity by increasing histone acetylation of the regulatory sequences of the Rac1 gene. Peripheral inflammation and synaptic maladaptation are in line with newly hypothesized clinical intervention targets for depression that are not addressed by currently available antidepressants.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-017-02794-5

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Oral administration of BDPP promotes resilience to RSDS. a Schematic design of the experiment. b Treatment with BDPP increases the proportion of mice showing a resilient phenotype, as measured by social interaction ratio (two-tailed unpaired t-test, t42 = 2.786, P = 0.008). c Representative heatmaps of social avoidance behavioral test. Graphs represents mean ± s.e.m., **P < 0.01
Fig. 1 Oral administration of BDPP promotes resilience to RSDS. a Schematic design of the experiment. b Treatment with BDPP increases the proportion of mice showing a resilient phenotype, as measured by social interaction ratio (two-tailed unpaired t-test, t42 = 2.786, P = 0.008). c Representative heatmaps of social avoidance behavioral test. Graphs represents mean ± s.e.m., **P < 0.01CC BY · PubMed Central
Fig. 2 In vitro screening of phenolic metabolites to modulate IL-6 and Rac1 and mechanistic investigation of the role of DHCA on IL-6 and Mal-gluc on Rac1. a, b Screening of the effect of plasma bioavailable phenolic metabolites in inhibition of IL-6 in PBMCs following LPS stimulation. a Primary screening of 14 plasma bioavailable phenolic metabolites (one-way ANOVA, F15,63 = 16.30, P < 0.0001, n = 3–8 per culture condition). b Dose response and EC50 calculations of the effects of DHCA on IL-6. c, d Screening of the effects of brain bioavailable phenolic metabolites in promotion of Rac1 expression in primary MSN-enriched cultures. c Primary screening of 9 brain bioavailable phenolic metabolites (one-way ANOVA, F9,39 = 5.32, P = 0.0002, n = 4 per culture condition). d Dose response and EC50 calculations of the effects of Mal-gluc on Rac1 expression. e The expression of de novo methylation/demethylation genes in PBMCs following DHCA treatment (two-tailed unpaired t-test, t12 = 3.220, P = 0.0074 for DNMT1, n = 7 per culture condition). f Assessment of methylation-mediated promoter-like activity of CpG-rich sequences in the regions of IL-6 promoter in transfected N2A cells in the presence or absence of methylation inhibitor AZA-DC or DHCA (one-way ANOVA, F5,17 = 1.278, P = 0.335). g Assessment of methylation-mediated enhancer-like activities of CpG-rich sequences in the regions of IL-6 introns in transfected N2A cells in the presence or absence of methylation inhibitor AZA-DC or DHCA (one-way ANOVA, F5,16 = 161.7, P < 0.0001 for intron 1; F5,17 = 25.54, P < 0.0001 for intron 3; F5,16 = 0.825, P = 0.558 for intron 4). h HDAC genes expression in MSN-enriched primary culture following Mal-gluc treatment (two-tailed unpaired t-test, t6 = 2.781, P = 0.0017 for HDAC2, n = 4 per culture condition). i, j Quantitative CHIP assessment of permissive H3 acetylation (i) and repressive trimethylation on H3K27 (j) along the mouse Rac1 promoter and upstream in MSN-enriched primary neurons following Mal-gluc treatment (two-tailed unpaired t-test, t8 = 8.284, P = 0.0071 for ~500 bp upstream; t8 = 13.5, P = 0.0017 for ~−50 bp in the promoter; n = 5 per culture condition for acetylation). All graphs represent mean ± s.e.m., **P < 0.01, ***P < 0.001
Fig. 2 In vitro screening of phenolic metabolites to modulate IL-6 and Rac1 and mechanistic investigation of the role of DHCA on IL-6 and Mal-gluc on Rac1. a, b Screening of the effect of plasma bioavailable phenolic metabolites in inhibition of IL-6 in PBMCs following LPS stimulation. a Primary screening of 14 plasma bioavailable phenolic metabolites (one-way ANOVA, F15,63 = 16.30, P < 0.0001, n = 3–8 per culture condition). b Dose response and EC50 calculations of the effects of DHCA on IL-6. c, d Screening of the effects of brain bioavailable phenolic metabolites in promotion of Rac1 expression in primary MSN-enriched cultures. c Primary screening of 9 brain bioavailable phenolic metabolites (one-way ANOVA, F9,39 = 5.32, P = 0.0002, n = 4 per culture condition). d Dose response and EC50 calculations of the effects of Mal-gluc on Rac1 expression. e The expression of de novo methylation/demethylation genes in PBMCs following DHCA treatment (two-tailed unpaired t-test, t12 = 3.220, P = 0.0074 for DNMT1, n = 7 per culture condition). f Assessment of methylation-mediated promoter-like activity of CpG-rich sequences in the regions of IL-6 promoter in transfected N2A cells in the presence or absence of methylation inhibitor AZA-DC or DHCA (one-way ANOVA, F5,17 = 1.278, P = 0.335). g Assessment of methylation-mediated enhancer-like activities of CpG-rich sequences in the regions of IL-6 introns in transfected N2A cells in the presence or absence of methylation inhibitor AZA-DC or DHCA (one-way ANOVA, F5,16 = 161.7, P < 0.0001 for intron 1; F5,17 = 25.54, P < 0.0001 for intron 3; F5,16 = 0.825, P = 0.558 for intron 4). h HDAC genes expression in MSN-enriched primary culture following Mal-gluc treatment (two-tailed unpaired t-test, t6 = 2.781, P = 0.0017 for HDAC2, n = 4 per culture condition). i, j Quantitative CHIP assessment of permissive H3 acetylation (i) and repressive trimethylation on H3K27 (j) along the mouse Rac1 promoter and upstream in MSN-enriched primary neurons following Mal-gluc treatment (two-tailed unpaired t-test, t8 = 8.284, P = 0.0071 for ~500 bp upstream; t8 = 13.5, P = 0.0017 for ~−50 bp in the promoter; n = 5 per culture condition for acetylation). All graphs represent mean ± s.e.m., **P < 0.01, ***P < 0.001CC BY · PubMed Central
Fig. 3 In vivo dose-finding and prophylactic effect of DHCA/Mal-gluc in promoting resilience to RSDS. a IL-6 levels in plasma 6 h post LPS challenge in mice treated with various doses of DHCA for 2 weeks (one-way ANOVA, F5,20 = 12.50, P < 0.0001, n = 3–5 animals per group). b Levels of Rac1 mRNA in the NAc from mice treated with various doses of Mal-gluc for 2 weeks (one-way ANOVA, F6,22 = 4.22, P = 0.01, n = 3–4 animals per group). c Schematic design of the experiment. d Representative heatmaps and scatter plots of social avoidance behavioral test in mice treated with vehicle or DHCA/Mal-gluc for 2 weeks with or without RSDS (one-way ANOVA, F3,64 = 2.79, P = 0.048). e Sucrose preference test performed 48 h and 72 h following the SI testing (one-way ANOVA, F3,38 = 5.53, P = 0.003 for 48 h and F3,38 = 6.73, P = 0.001 for 72 h). f Plasma levels of IL-6 24 h following the last defeat (one-way ANOVA, F3,35 = 6.25, P = 0.002, n = 7,8,11,10 mice). g Rac1 expression 48 h following the last defeat (one-way ANOVA, F3,37 = 4.81, P = 0.007). All graphs represent mean ± s.e.m., *P < 0.05, **P < 0.01
Fig. 3 In vivo dose-finding and prophylactic effect of DHCA/Mal-gluc in promoting resilience to RSDS. a IL-6 levels in plasma 6 h post LPS challenge in mice treated with various doses of DHCA for 2 weeks (one-way ANOVA, F5,20 = 12.50, P < 0.0001, n = 3–5 animals per group). b Levels of Rac1 mRNA in the NAc from mice treated with various doses of Mal-gluc for 2 weeks (one-way ANOVA, F6,22 = 4.22, P = 0.01, n = 3–4 animals per group). c Schematic design of the experiment. d Representative heatmaps and scatter plots of social avoidance behavioral test in mice treated with vehicle or DHCA/Mal-gluc for 2 weeks with or without RSDS (one-way ANOVA, F3,64 = 2.79, P = 0.048). e Sucrose preference test performed 48 h and 72 h following the SI testing (one-way ANOVA, F3,38 = 5.53, P = 0.003 for 48 h and F3,38 = 6.73, P = 0.001 for 72 h). f Plasma levels of IL-6 24 h following the last defeat (one-way ANOVA, F3,35 = 6.25, P = 0.002, n = 7,8,11,10 mice). g Rac1 expression 48 h following the last defeat (one-way ANOVA, F3,37 = 4.81, P = 0.007). All graphs represent mean ± s.e.m., *P < 0.05, **P < 0.01CC BY · PubMed Central
Fig. 4 Prophylactic treatment with DHCA/Mal-gluc reverses RSDS-induced synaptic structural and functional alteration in the NAc. a Immunochemistry quantification of PSD95 puncta in NAc (one-way ANOVA, F3,22 = 4.50, P = 0.015). Inset; representative images of PSD95 puncta, scale bar = 10 µm. b–e DHCA/Mal-gluc treatment regulates synaptic transmission in D2 neurons in the shell of NAc following RSDS. b Social avoidance test in the Drd2 mice (two-tailed unpaired t-test, t21 = 2.114, P = 0.047). c Representative traces of mEPSCs. d mEPSCs frequencies (two-tailed unpaired t-test, t46 = 2.890, P = 0.0059). e mEPSCs amplitudes (two-tailed unpaired t-test, t46 = 0.5008, P = 0.6189). All graphs represent mean ± s.e.m., *P < 0.05, **P < 0.01
Fig. 4 Prophylactic treatment with DHCA/Mal-gluc reverses RSDS-induced synaptic structural and functional alteration in the NAc. a Immunochemistry quantification of PSD95 puncta in NAc (one-way ANOVA, F3,22 = 4.50, P = 0.015). Inset; representative images of PSD95 puncta, scale bar = 10 µm. b–e DHCA/Mal-gluc treatment regulates synaptic transmission in D2 neurons in the shell of NAc following RSDS. b Social avoidance test in the Drd2 mice (two-tailed unpaired t-test, t21 = 2.114, P = 0.047). c Representative traces of mEPSCs. d mEPSCs frequencies (two-tailed unpaired t-test, t46 = 2.890, P = 0.0059). e mEPSCs amplitudes (two-tailed unpaired t-test, t46 = 0.5008, P = 0.6189). All graphs represent mean ± s.e.m., *P < 0.05, **P < 0.01CC BY · PubMed Central
Fig. 5 Therapeutic effect of DHCA/Mal-gluc in treating stress-induced depression. a Schematic design of the experiment. b–d Behavioral tests in stress susceptible mice following 2 weeks vehicle or DHCA/Mal-gluc treatment. b Social avoidance behavioral test (two-tailed unpaired t-test, t15 = 1.039, P = 0.3152). c Sucrose preference test (two-tailed unpaired t-test, t16 = 2.406, P = 0.029) and d splash test (two-tailed unpaired t-test, t16 = 2.539, P = 0.021). e Rac1 expression in the NAc (two-tailed unpaired t-test, t14 = 3.637, P = 0.003). f Schematic design of the experiment. g, h Behavioral tests following sub-threshold defeat in BM chimeras with BM reconstructed from naive mice or susceptible mice with or without DHCA/Mal-gluc treatment. g Social avoidance test (one-way ANOVA, F2,52 = 4.58, P = 0.015) and h sucrose preference test (one-way ANOVA, F2,56 = 6.17, P = 0.004). i Plasma level of IL-6 24 h after the sub-threshold defeat (one-way ANOVA, F2,49 = 6.98, P = 0.002). j–l DHCA/Mal-gluc treatment suppressed stress-induced increase of inflammatory Ly6Chi of monocytes and neutrophils in BM chimeras with BM reconstructed from susceptible mice. j Percentage of live leukocytes derived from the donor (one-way ANOVA, F2,28 = 3.13, P = 0.144). k Frequency of Ly6Chi monocytes of donor origin. Numbers represent percentages of live leukocytes (one-way ANOVA, F2,29 = 6.18, P = 0.006) and l frequency of neutrophils of donor origin. Numbers represent percentages of live leukocytes (one-way ANOVA, F2,28 = 5.377, P = 0.011). m, n Plasma levels of G-CSF and GM-CSF 24 h after the sub-threshold defeat (one-way ANOVA, F2,25 = 5.189, P = 0.0138 for G-CSF, F2,25 = 6.103, P = 0.0075 for GM-CSF). All graphs represent mean ± s.e.m., *P < 0.05, **P < 0.01
Fig. 5 Therapeutic effect of DHCA/Mal-gluc in treating stress-induced depression. a Schematic design of the experiment. b–d Behavioral tests in stress susceptible mice following 2 weeks vehicle or DHCA/Mal-gluc treatment. b Social avoidance behavioral test (two-tailed unpaired t-test, t15 = 1.039, P = 0.3152). c Sucrose preference test (two-tailed unpaired t-test, t16 = 2.406, P = 0.029) and d splash test (two-tailed unpaired t-test, t16 = 2.539, P = 0.021). e Rac1 expression in the NAc (two-tailed unpaired t-test, t14 = 3.637, P = 0.003). f Schematic design of the experiment. g, h Behavioral tests following sub-threshold defeat in BM chimeras with BM reconstructed from naive mice or susceptible mice with or without DHCA/Mal-gluc treatment. g Social avoidance test (one-way ANOVA, F2,52 = 4.58, P = 0.015) and h sucrose preference test (one-way ANOVA, F2,56 = 6.17, P = 0.004). i Plasma level of IL-6 24 h after the sub-threshold defeat (one-way ANOVA, F2,49 = 6.98, P = 0.002). j–l DHCA/Mal-gluc treatment suppressed stress-induced increase of inflammatory Ly6Chi of monocytes and neutrophils in BM chimeras with BM reconstructed from susceptible mice. j Percentage of live leukocytes derived from the donor (one-way ANOVA, F2,28 = 3.13, P = 0.144). k Frequency of Ly6Chi monocytes of donor origin. Numbers represent percentages of live leukocytes (one-way ANOVA, F2,29 = 6.18, P = 0.006) and l frequency of neutrophils of donor origin. Numbers represent percentages of live leukocytes (one-way ANOVA, F2,28 = 5.377, P = 0.011). m, n Plasma levels of G-CSF and GM-CSF 24 h after the sub-threshold defeat (one-way ANOVA, F2,25 = 5.189, P = 0.0138 for G-CSF, F2,25 = 6.103, P = 0.0075 for GM-CSF). All graphs represent mean ± s.e.m., *P < 0.05, **P < 0.01CC BY · PubMed Central
Fig. 6 Prophylactic treatment with DHCA/Mal-gluc attenuates variable stress-mediated depression and anxiety phenotypes in both male and female mice. a Schematic design of the experiment. b–e Behavioral responses of male mice following 21 days of CVS. b Splash test (one-way ANOVA, F3,38 = 4.61, P = 0.008). c NSF test (one-way ANOVA, F3,39 = 3.23, P = 0.034). d FST (one-way ANOVA, F3,39 = 10.30, P < 0.0001) and e sucrose preference test (one-way ANOVA, F3,37 = 1.65, P = 0.197). f–i Behavioral responses of female mice following 6 days of SCVS. f Splash test (one-way ANOVA, F3,39 = 5.33, P = 0.004). g NSF test (one-way ANOVA, F3,39 = 5.22, P = 0.004); h FST (one-way ANOVA, F3,39 = 0.581, P = 0.631) and i sucrose preference test (one-way ANOVA, F3,37 = 3.312, P = 0.032). All graphs represent mean ± s.e.m., *P < 0.05, **P < 0.01, ***P < 0.001
Fig. 6 Prophylactic treatment with DHCA/Mal-gluc attenuates variable stress-mediated depression and anxiety phenotypes in both male and female mice. a Schematic design of the experiment. b–e Behavioral responses of male mice following 21 days of CVS. b Splash test (one-way ANOVA, F3,38 = 4.61, P = 0.008). c NSF test (one-way ANOVA, F3,39 = 3.23, P = 0.034). d FST (one-way ANOVA, F3,39 = 10.30, P < 0.0001) and e sucrose preference test (one-way ANOVA, F3,37 = 1.65, P = 0.197). f–i Behavioral responses of female mice following 6 days of SCVS. f Splash test (one-way ANOVA, F3,39 = 5.33, P = 0.004). g NSF test (one-way ANOVA, F3,39 = 5.22, P = 0.004); h FST (one-way ANOVA, F3,39 = 0.581, P = 0.631) and i sucrose preference test (one-way ANOVA, F3,37 = 3.312, P = 0.032). All graphs represent mean ± s.e.m., *P < 0.05, **P < 0.01, ***P < 0.001CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 70 references

Cited by

See all 274

Metadata

Authors
Wang, J., Hodes, G. E., Zhang, H., Zhang, S., Zhao, W., Golden, S. A., Bi, W., Menard, C., Kana, V., Leboeuf, M., Xie, M., Bregman, D., Pfau, M. L., Flanigan, M. E., Esteban-Fernández, A., Yemul, S., Sharma, A., Ho, L., Dixon, R., Merad, M., Han, M.-H., Russo, S. J., & Pasinetti, G. M.
Affiliations
  • James J. Peters VA Medical Center (US)
  • Icahn School of Medicine at Mount Sinai (US)
  • Tisch Cancer Institute (US)
  • University of North Texas (US)
Corresponding author
Pasinetti, Giulio M.
Venue
Nature Communications
Published
2018-02-02
Volume
9
Issue
1
Pages
477-477
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2794098750
Cited by
274
References
70
Citations by year
2026: 12 · 2025: 26 · 2024: 40 · 2023: 46 · 2022: 31 · 2021: 39 · 2020: 32 · 2019: 28 · 2018: 18
FWCI
9.31
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • University of North Texas Digital Library (University of North Texas) (submittedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
  • VTechWorks (Virginia Tech) (submittedVersion)
Funders
  • National Science Foundation (P50 AT008661-01)
  • Office of Dietary Supplements (AT008661-01, P50 AT008661-01)
  • U.S. Department of Veterans Affairs (IK6 BX003785)
  • National Institutes of Health (NSF81200862, NIH-R01, MH104559)
  • Geriatric Research Education and Clinical Center
  • National Institute of Mental Health (R01MH090264, R21MH112081, P50MH096890, R01MH104559)
  • National Center for Complementary and Integrative Health (P50AT008661, AT008661-01, AT008661)
Topics
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
Keywords
major depressive disorder, stress resilience, chronic stress, epigenetics, synaptic plasticity, peripheral inflammation, dihydrocaffeic acid, malvidin-3-glucoside, phytochemicals, interleukin-6, DNA methylation, histone acetylation, Rac1, hematopoietic progenitor cell transplantation, depression-like behavior, antidepressant targets
MeSH terms
Interleukin-6 Inhibitors, Animals, Anthocyanins, Caffeic Acids, Depression, Drug Evaluation, Preclinical, Glucosides, Inflammation, Male, Mice, Inbred C57BL, Neuronal Plasticity, Neuropeptides, Social Behavior, Stress, Psychological, Interleukin-6, Leukocyte Common Antigens, CpG Islands, rac1 GTP-Binding Protein, Epigenesis, Genetic, Polyphenols

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Epigenetic modulation of inflammation and synaptic plasticity promotes resilience against stress in mice. https://app.cochat.ai/papers/10.1038/s41467-017-02794-5
The paper
Wang, J., Hodes, G. E., Zhang, H., Zhang, S., Zhao, W., Golden, S. A., Bi, W., Menard, C., Kana, V., Leboeuf, M., Xie, M., Bregman, D., Pfau, M. L., Flanigan, M. E., Esteban-Fernández, A., Yemul, S., Sharma, A., Ho, L., Dixon, R., . . . Pasinetti, G. M. (2018). Epigenetic modulation of inflammation and synaptic plasticity promotes resilience against stress in mice. Nature Communications. https://doi.org/10.1038/s41467-017-02794-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.